FDA approval is what will ultimately deliver the biggest spike in value to the company. Hard to see at this stage why that won't be forthcoming once the application is made given the safety and efficacy. In other words, by around this time next year Spontan could be in market in the US and the magnitude of that outcome cannot be understated. Also the company will be looking into a US listing given what is ahead. Of course, every chance the company may be made offers it cannot refuse ahead of such inflection points.
ED Game Changer, page-13
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LTP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.5¢ |
Change
0.145(17.7%) |
Mkt cap ! $81.82M | |||
| Open | High | Low | Value | Volume |
| 85.0¢ | 96.5¢ | 85.0¢ | $1.072M | 1.169M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.5¢ | 4999 | 1 |
View Market Depth
| Last trade - 16.10pm 12/08/2024 (20 minute delay) ? |
| LTP (ASX) Chart |